Advocacy intelligence hub — real-time data for patient organizations
UNICANCER — PHASE2
Multitude Therapeutics Inc. — PHASE1, PHASE2
Novartis Pharmaceuticals — PHASE1, PHASE2
The Christie NHS Foundation Trust
M.D. Anderson Cancer Center — PHASE1, PHASE2
M.D. Anderson Cancer Center — PHASE2
National Cancer Institute (NCI) — PHASE1, PHASE2
Indiana University
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Andrea B Apolo
National Cancer Institute LAO
📍 Birmingham, Alabama
BioNTech Responsible Person
BioNTech SE
Fu Zhao
Beijing Neurosurgical Institute
📍 BROOKLYN, NY
Pinan Liu
Beijing Tiantan Hospital
Carl M Gay, MD,PHD, M.D., Ph.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Ann (Annie) W Silk
Dana-Farber - Harvard Cancer Center LAO
📍 Los Angeles, California
View all Neuroendocrine tumor with other location specialists →